Gregor founded Pharmacentric Solutions Ltd in late 2017 to deliver consultancy services for the Pharma Industry specialising in device and packaging development and strategies from early concept through to commercial supply. Prior to this Gregor was Senior Design Director at GSK and Device and Packaging subject matter expert, based at Ware, UK. Gregor is a device and packaging specialist with over 30 years experience working in both the surgical and pharmaceutical industries. He has a B.Sc. in Industrial Design and a M.Sc. in Polymer Science and Engineering and after completing a Postgraduate in Marketing in 1986 he worked for Smiths Industries Medical Systems specializing in surgical equipment design. In 1989 he joined the Device Development Unit at GSK R&D. He worked as design director on GSK platforms including injectable and respiratory devices and packaging. In 2009 Greg moved to GSK Manufacturing as Global Head ofTechnical Packaging where he was responsible for all Technical Packaging projects. More recently he has focused on supporting the launches of the Ellipta Inhaler, respiratory training devices and researching and preparing GSK’s respiratory and packaging strategies for emerging markets. In 2016 he represented GSK on the Medicines Manufacturing Industry Partnership and wrote and published the Technology and Innovation road map for UK Pharma. He holds over 40 patents and has presented widely on topics such asDigital, Patient Centric Design and Pharma road mapping. Gregor is also a Fellow of The Packaging Society and represents Pharma on the TPS Board and had been a judge on the Royal Society of Arts SDA Awards for the past 18 years.
Aurelio is a Senior Consultant in the European Thought Leadership team based in IQVIA’s London office.
His primary focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse in biosimilars, generics and value added medicines. He is considered a subject matter expert in these areas where he speaks at numerous conferences worldwide, presents to clients and engages in consulting projects in an advisory capacity.
Prior to IQVIA, Aurelio has worked as a strategy consultant in Life Sciences for LEK and Accenture and in R&D for Pfizer and GlaxoSmithKline.
Sagar currently works as a Global Marketing Manager at BD wherein his responsibilities entail understanding clinician needs in the acute care segment as well as developing pre-fillable syringe solutions to most closely address those needs.
Sagar holds a MBA from Texas Christian University, USA and also a Bachelor’s in Electrical Engineering from National Institute of Technology, India.
In the past 10 years within Flex Tommaso Borghi led R&D teams through the development of connected devices for top medical devices and pharmaceutical companies working in close collaboration with marketing departments, top design firms and production sites around the world. He created partnerships with Italian universities and led programs with European research centers to bring cutting-edge technologies into the market. He holds several patents and published research papers in international peer-reviewed journals. Tommaso holds a PhD in Electrical Engineering from Politecnico di Milano and worked as Visiting Scientist at the Massachusetts Institute of Technology on the development of Brain Machine Interfaces.
Laurence BOURET is a waste management expert for 15 years. She started her career in the public sector (local authority) before joining the car industry. She dedicated 5 years to her children before developpingalongside Jacques PELISSARD, former MP and former President of the French Mayor’s Association, the first national resource center for Waste Management. Since 2013 she manages a unique and pecular nonprofit EPR program called DASTRI. Financed by the health industry and approved by 3 Ministries, DASTRI is a network of 18000 collection points (mosly pharmacies) offering to homecare patients a safe solution for their sharps*.She is also a member of the National Commission for EPR programs in France and has engaged a long term thinking with all stakeholders about the future of EPR programs facing challenges such as the move toward ambulatory care or the development of connected medical devices. * Since 2013 DASTRI has distributed 10 Mio of sharp containers and collected 4 billion of used medical devices
1982 Pharmacist degree option Biology, Paris X
1986 Official Bernay installation 27300.
1989 Election to the CROP - Regional Council of Pharmacists of Upper Normandy
1991 Founder of Pharma Reference (PHR Group), group of community pharmacists
CEO of the PHR Group.
1998 Expert at Afssaps: National Commission of Material Safety and AMM Commission GT CPD - Expert at ANAES and DHOS, group: Chemotherapy at Home.
Founder and President of HOPADOM, network of health professionals for the sick at home, Upper Normandy
2001 President of CROP Haute Normandie. Member of the Central Council Office of
the Order of Community Pharmacists. CCA.
2003 Expert at CNIB: Home Chemotherapy.
David Braun is Global Head of Medical Device Business Solution for Merck Healthcare. David is an executive leader that has 20 years of experience in research and development, operations, strategy and business management working in Europe, USA and Asia, in startups and large multinational companies. Through his career David gained significant experience designing winning organizations, leading and coaching cross functional teams bringing innovative products from ideation to launch. David is actually a Board director of Cellect, a biotech startup active in the field of stem cells and medical devices.Before joining Merck, David served as Head of Operations and Global R&D of the Technology Business unit at Newell Brands, a Fortune 500 company, where he led key growth initiatives and multimillion dollar projects.Prior to that, he worked as Vice President of R&D and Operations at Biosafe SA a medical device company recently acquired by GE, developing and launching products in the field of stem cell banking and cellular therapies. Previously, David also held various senior management and engineering roles in the aerospace and high tech industry.David holds a Master degree in applied physics from the Louis Pasteur University and a Degree in Electro-Optical Engineering from the Jerusalem College of Technology. He has participated in Executive leadership and general management programs at the Harvard Business School and IMD.
Iryna Bursuk is the Chief Operating Officer of the data science company StartUsInsights. Since 2014, Iryna has been scaling StartUs Insights’ operations in Austria (HQ), Ukraine and India. Together with her teams of analysts, data scientists and visualization experts, she provides actionable insights into startup-driven innovation for the industry leaders worldwide.
Florence Buscke is Senior Global Product Manager, heading the Product Management for Bulk Ampules, Cartridges and Vials at SCHOTT Pharmaceutical Systems .
Giana Carli Lorenzini has a PhD in Packaging Logistics from Lund University, Sweden, where she now works as a postdoctoral research fellow. In her research, Giana has investigated the complexities that surround the industry processes of innovating and designing inclusive pharmaceutical packaging. Importantly, in an aging world, it is of utmost importance to provide people with pharmaceutical packaging that enables the patient to correctly administer and follow their treatment. In her talk, she will address main findings of research about the challenges and opportunities in the pharmaceutical and packaging industry to design and innovate packaging that can result in better care and better patient outcomes.
As a pharmacist and after two previous professional experiences : the first in a pharmaceutical firm and the second in the French Authorities, I have almost 20 years of experience in the Leem in the field of pharmaceutical quality. As Pharmaceutical Affairs Director, I have the leadership for responding to enquiries and needs in various domains as quality regulation, bioproduction and biodevelopment regulation, management of the pharmaceutical sites and activities of the responsible pharmacist and thus to fulfil the role of interlocutor between the Pharmaceutical Industry and the National Authorities, and particularly with the inspection of ANSM (the French Medicines Agency) or with the Health Ministery. Otherwise I work every day with sister-Associations.
The Leem is the French pharmaceutical Industry Association and federates more than 95 per cent of companies in France. Its main role is to act as a coordinator between its members to better influence the pharmaceutical environment, in its large expertise field: scientific, legal, economic, industrial, training, communication.
Michelle has 15 years’ experience working in the environmental compliance sector building an extensive knowledge of the industry. After graduating from Cardiff University in 2002, she has developed her career by specialising in product stewardship, producer responsibility programs and their impacts on the producers.Co-Founding Lorax Compliance Limited in 2014, Michelle supports a diverse range of businesses with specialist Extended Producer Responsibility (EPR) reporting services as well as tailored consultancy covering all aspects of this environmental legislation. The award-winning solutions offered by Lorax Compliance improve methods of data management, provide comprehensive knowledge and present complete transparency into the costs of EPR compliance. EPR is a frequently changing and growing global field illustrated by increasing complexity and cost. Michelle’s focus within Lorax is to promote and simplify the vast range of reporting requirements their clients find themselves obligated by.
Andrew leads the development of Portal's disposable system. His background in electromechanical systems as well as high-volume mechanical devices supports Portal in the development of a scaleable system. Previously, Andrew was the first engineering hire at Fractyl, a surgical startup that he saw through first-in-human clinical testing. Prior to Fractyl, Andrew was at Cambridge Consultants where he developed drug delivery products for clients ranging from startups to large pharmaceutical companies. Andrew has a BS in Mechanical Engineering from FW Olin College of Engineering.
Dr Cole gained his PhD in Solid State Physics of Giant Magnetoresitive Materials grown by Molecular BeamEpitaxy at the University of Leeds in 2004. He then went on to work for Narec, the UK’s NationalRenewable Energy Centre in the Photovoltaics division where he initially worked as a Process Technologistand later a Business Development Manager. During this time, Dr Cole was part of the team responsible fora world record in photovoltaic conversion efficiency for multicrystalline solar cells. Subsequently, whenfaced with a change in government priorities and a reduction in funding for Photovoltaics, Dr Cole led aprocess of inward investment from a Swedish Greentech company leading in the separation of the Narecphotovoltaics division into a separate company, Narec Solar. Dr Cole was appointed Managing Director ofthis company. Dr Cole then went on to work as Chief Scientist at PolyPhotonix, leading a team of 5 scientists to developorganic light emitting technology for a wearable device that provides sight saving retinal treatments. Thedevice is now available commercially in a number of countries.At the start of 2017, Dr Cole moved to CPI and is working within the Strategic Marketing team within theremit of printable electronics for smart supply chains and smart pharmaceutical packaging. He recently ledan initiative to understand the capability requirements for a centre of excellence in smart pharmapackaging. He is currently leading the CPI Strategic Marketing Smart Packaging Initiative and is keen to helpsupportthe development and scale up of innovations that will improve supply chains, reduce wastage andimprove patient outcomes.
Pari is a senior innovation professional, who specialises in identifying, building and validating newopportunities for major global companies and emerging start-ups. He has 10 years of experience of leading innovation and strategy projects for many of the world’s largest medical device and pharmaceutical companies, with a focus on discovering opportunities through user, market and technology insights. Project have included the development of broad biosimilar defence strategies, the development of disruptive propositions from unmet clinical needs and IP landscaping activities to identify white spaces in crowded areas. He has worked within consulting and corporateenvironments, with a focus on understanding the issues in the “real-life” implementation of new opportunities for innovation. Pari has additionally led innovation and strategy programmes in multiple other industries,including FMCG, consumer health, drug delivery, surgical and critical care; specialising in lifesciences and diagnostics. Through these wide-ranging experiences, he has created and used manydifferent tools for innovation, to capture the lessons learned and to enable the efficient discovery ofboth innovative and robust new offerings in different markets.By background, Pari has a BSc in Biochemistry and a PhD in Genetics, with a specialism in thecommercialization of early-stage technologies.
Graduating as a pharmacist in 1989, Isabelle Debrix oriented her career towards hospital pharmacy. She was appointed Hospital Practitioner in 1995 at Hospital Tenon where she then served as the Pharmacy Department Head from 2009 to 2014. Presently Dr. Debrix manages the Medication Department for the Eastern Parisian Hospital Group including hospitals Saint Antoine, Tenon, Trousseau, Rothschild and Laroche Guyon.
Earning her PhD in 1994, Dr. Debrix pursued studies in medical and biological ethics and focused her research on the medical guidelines and proper use of oncological medicines. Part of this work was the subject of her 2002 post doctoral dissertation. She is the author or co-author of 24 international publications.
Dr. Debrix continues to engage in research and encourages the involvement of her team to evaluate professional pharmacy practices and develop innovative methods.
Her current research topics focus particularly on securing the delivery of medication to patients.
As a senior consultant, Alex takes a lead role in projects from immersion and concept generation through to detailed design and development. Alex’s background in mechanical engineering enables him to balance user requirements with technical considerations whilst developing commercially viable products. Alex works closely with his colleagues in the human factors and engineering teams to quickly translate research insights into tangible designs which improve the experience of the end user.
Alex has over 10 years’ experience in consultancy and design research in London and Cambridge. His consultancy work has seen him tackle a range of consumer products and medical devices, whilst his spell as a researcher involved collaboration with scientists at the University of Cambridge on the development of early-stage science and technology. He has also been involved in several innovation projects aimed at defining new product and service offerings for major clients.
For more than 20 years at SANOFI, David Dronneau, was involved in the IT department in the first electronic submissions of dossier (NDA) and on electronic clinical trials before turning towards setting implementation of innovation process. For 4 years, he joined Clinical Supplies department as responsible Technologies, Innovation, and Process Solutions with a main objective: To develop innovative packaging that meets patient needs in following mainly three directions: Ensuring patient safety, improve usage and how to help improve patient compliance while ensuring continuity of operation in terms of development of solution and processes and finally ensuring the dissemination of business excellence good practices (LEAN) in the unit.
Pascale Farjas is the Global Category Manager for the ENT (ear, nose, and throat) segment at Nemera, a leading developer and manufacturer of healthcare packaging and devices. Her role encompasses understanding patients’ needs and regulatory requirements to develop and market packaging solutions that improve the patient experience. She is in charge of the market introduction of new pump platforms for nasal
sprays. Pascale joined Nemera in 2011 and holds a chemical engineer degree from the National Institute of Applied Sciences of Rouen in France, completed with a marketing-focused Master Degree from the Business Administration Institute (France).
Martin Folger is currently (since September 2018) Head of Risk Management Sciences, Compliance and Quality within the global function Pharmaceutical Sciences at Boehringer Ingelheim Vetmedica GmbH. He is a pharmacist and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig, Germany. After starting his career working in pharmaceutical manufacturing of oral solid dosage forms for two years for a major US-based pharmaceutical company, he joined the Animal Health business of Boehringer Ingelheim in 1997 as a manager in formulation development. From 2002 until September 2018 he was Head of Global CMC Development Pharmaceuticals and responsible for all CMC-related activities including e.g. packaging development. He currently also has the role as the Qualified Person for investigational veterinary product.
Olivier is currently Product Manager at LASEA. Within the Sales and Marketing department he supports the business development of laser marking and micromachining solutions.
After starting his career in product development in the energy field (ABB), Olivier joined LASEA in 2011 as a project manager. He worked on several projects for the MedTech, photovoltaics and watch industry.
He has a Master in Physical Engineering and in General Management.
Stéphanie Francart joined VCLS in August 2018. She participates in the preparation of medical devices regulatory strategies and operational activities – from early development phases to technical files preparation and post-market medical surveillance. With over 13 years of medtech practice, particularly at French competent authority ANSM and notified body GMED, Stéphanie has gained experiences covering the different phases of the life cycle of medical devices.
Chris Franzese is Clinical Leader at Matchstick. He manages a team of clinicians supportingclient projects related to combination product and medical device development and usabilitytesting, leads the company’s clinical
Page 3of 11training, and is accountable for making clinical knowledgeaccessible and relevant to client projects. An experienced clinical trial researcher, Dr. Franzesehas numerous peer-reviewed publications related to usability research for connected medicaldevices, antiplatelet therapies in coronary artery disease, and clinical laboratory testing. He hasa BS in Biology from Loyola University, an MHS in Health Informatics and a PharmD both fromFairleigh Dickinson University. He is a licensed pharmacist.
Andy is the founder of Cambridge-based Team Consulting, an award-winning medical device design and development consultancy. Andy is a mechanical engineer by profession, with over 25 years’ experience in medical device development. He has played a leading role in developing Team’s drug delivery business, both in technology development and in development of partner relationships. With a background in materials processing and manufacturing automation, he is committed to transferring best practices from manufacturing industry to the pharma and medical sector. An active member of industry associations including the PDA and Aerosol Society, he is also a UK accredited expert serving on the ISO committee developing standards for parenteral delivery devices.
Frédéric Gabriel is Chief Innovation Officer for the Haselmeier Group and General Manager of Haselmeier Switzerland. He oversees strategic innovation activities as well as product innovation, pre-development and portfolio management. Frédéric Gabriel joined Haselmeier in 2008 and was responsible for the Project Business. Prior to Haselmeier, Frédéric Gabriel worked as Business Analyst at Capgemini in the European Biotech Group in Stuttgart before joining Genzyme in 2005. At Genzyme, he worked as Business Analyst and later as Program Manager for the European Cardiovascular Business Unit, responsible for the European launch of Genzyme’s first cardiovascular product. He holds a MSc in Biology from the École Normale Supérieure in Paris and a M.B.A. from the European School of Business, ESCP-EAP.
Dr Pascale Gauthier is Pharmacist (D.Pharm) she got Masters in Biopharmaceutical (‘New gelification method’), a specific Master (DEA) in Pharmacokinetics (‘Pharmacokinetic study on hypertensive drug...’) and PhD in Pharmaceutical Technology (‘Rotogranulation process for manufacture spheres’) form Auvergne University. She is in charge of Marketing and Design courses in the Faculty of Pharmacy of Clermont-Ferrand, and wasinvolved in several patents, international publications and conferences. Her researches were focused on modified release forms, pharmaceutical design & categories of users, digital in health area and she has been invited speaker in various international events (Drug Formulation Strategies, Pharmapack, ADF, PCD, Glatt Technology Training Center) and various judging committees (WorldPack, Pharmapack, CPhI).
Pr Anne Gayot, Pharmacist, co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France, member of the French Pharmaceutical and Generic working group of ANSM
Professor Anne GAYOT is in co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France.This laboratory, beyond its teaching activities in the field of the development and production of pharmaceutical products, studies the solid state properties and properties of the particulate solid of the raw materials used in the formulation of drugs.It studies the physical properties of excipients and active substances with respect to functionnality characteristics.Professor Anne GAYOT was until reorganisation of the french agency member of the French Marketing authorization committee She is now member of the French Pharmaceutical and Generic working group at the French Agency. She participates to the writing of the guideline on Pharmaceutical Development of Medicines for Paediatric Use. She is the chair of the Functionnality Group related characteristics of the European Pharmacopoeia.She prepared her phD at the University of Lille (1981). It concerns microcapsules of activated charcoal for renal patients.Her scientific work concerns chacterisation of solid particles, extrusion-spheronisation, powder for inhalation. She is in charge of the master in industrial pharmaceutics.
Scott Gibson was recruited to Amgen in 2012 to build Amgen’s Advanced Device Technologies and Innovation Organization and since 2016 heads Amgen’s Device Technologies Innovation Center in Cambridge, Massachusetts. These organizations are responsible for identification and advancement of device technologies with application to Amgen’s product and portfolio strategies. Scott previously directed development for multiple drug delivery companies in treatment of diabetes, spasticity, and chronic pain resulting in acquisition by Medtronic and Boston Scientific. Scott earned his Bachelor's degree in Mechanical Engineering from California Polytechnic State University, San Luis Obispo, and currently holds 29 US patents in drug delivery and cardiac rhythm management.
Daniele has over 10 years’ experience of purchasing in Global Pharmaceutical Manufacturing and Supply Chain environments. He has held roles with increasing responsibility in multiple locations across Europe. At Abbott Laboratories, he enhanced his procurement expertise and pharmaceutical knowledge while based at a manufacturing plant in Italy, in the divisional offices in London & Dublin and also in the headquarters in Basel.
Daniele joined Ferring HQ near Lausanne (CH) in October 2013 as Global Category Manager, in charge of the global purchasing strategy and its execution for key packaging materials and medical devices used in Ferring Finished Products.
Daniele was appointed Head of Purchasing, Solids and Packaging Cluster in February 2017 and Director of Product Supply Direct Procurement in November 2017.
Daniele has a Masters Degree in Industrial Engineering from the University of Rome, Italy, followed by an MBA at the UCD Michael Smurfit Graduate Business School, Dublin, Ireland.
Gregory is a EO Technical Director EMEAA within Sterigenics. He is responsible for the development of new cycles, customer validation, and R&D projects. He is a leader in validation, development, and cycle design and improvements in the EMEAA regions. Gregory is an active trainer who enjoys sharing his knowledge with others through formal seminars at trade shows, as well as informal customer training. He has been published in Medical Design & Outsourcing and Med Device Online Gregory is also a member of ISO TC198 – WG1 for EO sterilization representing Belgium in the ISO committee.
Education: Master in Industrial Chemistry from Engineering High School, Liège (Belgium); Business Administration Certification, Cambridge (UK)
Expertise: Ethylene Oxide Sterilization Validation of Medical Devices, Cycle Development, Medical Device Consulting, Gas Chromatography Method Validation, Failure Investigations
Carolin Grandt studied industrial engineering at the Cooperative University of Baden-Württemberg in cooperation with TSS Germany. From 2010, she worked in various functions in sales before she switched in 2015 to TSS Stein am Rhein/Switzerland as Product Manager. In this function, she manages and coordinates customer projects in the area of LSR and LSR-two-component parts together with the customers, the engineering team and the sales department. Since 2017, she is also in charge of the Commercial Department at TSS Stein am Rhein, which includes Product Management, Customer Service, Purchasing and Production Planning.
Paul heads up Team’s design group, working closely with clients and colleagues to improve the user experience of medical devices through design. Paul is a passionate advocate of the importance of ‘design thinking and is involved in all stages of product development, from front-end innovation to detailed design for manufacture.
During his time at Team, Paul has led the design and project management of many innovative products including inhalers, injectors, surgical instruments, diagnostic platforms, child resistant packaging and consumer medical products. He is particularly focused on ensuring the right direction is set from the outset, that user needs are thoroughly understood and represented throughout.
Currently Business Development Director at BIOCORP, in charge of seeking partnerships with pharma
companies or disease management platforms to customize BIOCORP’s existing range of connected
devices in the fields of injection and respiratory, and exploring opportunities for on demand programs.
Before joining BIOCORP, he was a consultant for a firm specialized in Healthcare. He also worked in the
pharma industry for Sanofi, and in the health insurance sector at AXA. In terms of academic background,
he graduated from HEC, a European business school, with a major in strategy. He also has a degree in
political sciences and public affairs
A pharmacist specializing in regulatory affairs, access to the market and reimbursement of innovative medical technologies, he accompanies these companies on the French and international markets.
After starting his career as a university lecturer and researcher, he joined the pharmaceutical industry, then the world of medical devices, in international companies and professional associations, where he held various management positions, notably in Research & Development, Regulatory Affairs, Quality Assurance and Market Access as well as Medico-Economic Evaluation.
Mr. Hiroki Hasegawa is a researcher of Advanced Business Development Division.
He gained a Diploma in Science in 2013 and a Master Degree of Science in 2015 from Osaka University.
Since April 2015 he has been working for Mitsubishi Gas Chemical Company, Inc.
and in charge of macromolecular science, especially in composition development of thermosetting resin.
Since 2018 he has joined a development team of multilayer plastic vial & syringe for biologics.
After being graduated as a veterinary surgeon from the National Veterinary School of Toulouse, and some years being a practitioner and assistant in Parasitology, Bertrand Havrileck starts its career in the pharmaceutical industry in regulatory affairs and pre-clinical and clinical development. After some years in Bayer Pharma animal health then in Merck Sharp & Dohme, he joined Virbac Animal Health, where he headed successively regulatory affairs, pharmaceutical R&D, Europe R&D (Regulatory Affairs, Pharmaceutical R&D, Biological R&D) and since 2015 the Corporate Pharma R&D with 200 people. As part of the group of people in charge of Product Innovation in Virbac, his research interests include innovative packaging development dedicated to better use of the medicinal products i.e. ergonomy, safety, compliance, stability, ecology. He created a R&D packaging development group within the Corporate Pharma R&D dedicated to the development of new and innovative packaging resulting in 3 Pharmapack awards and 2 patents.
With +25 years experience Jesper Holm and his team has developed an IT driven manufacturing platform for pharmaceutical boxes that significantly reduces the lead time of secondary packaging to a few days.
This disruptive approach gives GraphcWest a very high growth in Europe and in the US.
Opening new factory near-site or on-site with pharmaceutical customers.
Samira Jafari is the head of Innovation department in Sulzer Mixpac. She holds a PhD degree in Mechanical and Fluid Engineering from ETH Zürich and has been with Sulzer Mixpac since 2014.
Sulzer Mixpac (part of Sulzer’s Applicator Systems Division) is a leading global company in the field of functional packaging and fluid applications and provides future-oriented products and innovative services for the application, mixing and delivering of liquids. Mixpac develops and manufactures plastic products, assemblies and devices for wide range of applications and industries ranging from dental and healthcare to manufacturing and renewable energies. Its strength is the creativity in the development and offering of new products and solutions with the highest quality.
Christa is the Director of Global Product Management, Prefilled Systems and Delivery, at West Pharmaceutical Services, Inc. Christa holds a diploma in Biomedical Engineering from the University of Aachen. She has worked within the pharmaceutical industry for more than 20 years. Christa gained experience as Quality Assurance Manager in one of the world’s leading pharmaceutical companies in sterile filling and packaging. In addition, she spent several years with the leading prefillable syringe manufacturer in the Customer Quality Assurance department. She joined West in 2005 and developed an expertise in prefillable systems and delivery technology in the Technical Customer Service and Marketing departments. Christa has held her current position since 2016.
Lionel Jeannin is an Arts & Métiers ParisTech Engineer with a Master degree in Business Administration from IAE Aix-en-Provence. He has more than 17 years’ experience in the Medical Device and Pharmaceutical industry. He held Project Manager and Development Team Manager positions in the Industrial Engineering, Medical Devices for eye surgery, Parenteral Nutrition and OTC/Rx Pharmaceutical domains. He had the Global responsibility of Packaging Development for OTC Brands like Voltaren, Nicotinell and Fenistil and is currently in charge of Device & Packaging Development projects for new oral medications at Novartis Pharma AG. He is also a member of Novartis Pharma Drug Delivery e-Device / Digital Development network.
Sustainability Manager at Amcor Flexibles Europe Middle East and Africa, Isabelle JENNY holds an engineer degree in polymer chemistry from the University of Pierre and Marie Curie in Paris and a PhD in Polymer Chemistry.She has been with Amcor since 2003 as a packaging development engineer and then as sustainability manager. Isabelle has more than 15 years’ experience inlife cycle assessment and eco-design study in the food, pharmaceutical and medical flexible packaging market.She has also an expertise in sustainable sourcing, on biodegradable and compostable packaging and on flexible packaging recyclability.She is involved in the several EU initiatives like: -CEFLEX project were the objective is to at drive development of recycling options for flexible packaging in Europe (also building on the U.K.-focused REFLEX project)-EU PEF Wine Pilot were the objective is to develop a robust and science-based methodology to measure the environmental performance of wine products from a cradle–to-grave perspective, and appropriate solutions to communicate the life cycle environmental performance of wines -ASI (Aluminium Stewardship Initiative) were the objective is to implement Responsible Aluminium within Amcor Flexibles Europe Middle East and Africa
Adam Kalbermatten serves as Global Director of Marketing at Terumo. He isresponsible for overseeing the Terumo Pharmaceutical marketing team that developsand markets drug delivery devices and combination products to meet the unique needsof pharmaceutical companies. Prior to joining Terumo in 2015, Adamheld variousoperations and commercial leadership roles at both Becton Dickinson (BD) and Merck.Adam holds a Bachelor of Engineering in Mechanical Engineering and a Masters ofEngineering in Engineering Management from Stevens Institute of Technology andaMBA from Columbia University.
A passionate individual with extensive experience in Operations, Engineering & Supply Chain
dedicated to supporting the United Nations Sustainable Development Goals by influencing and
directing industries through the deployment and utilization of enabling technologies.
Teddy is Mechanical Engineer graduated from the Engineer School “Institut Catholique d’Arts et Métiers” in France. He also has a Master Degree in Mathematics.
Teddy has worked first in Automotive (Arvin Meritor) and Energy (GE) fields. Then he joined the pharmaceutical industry as a consultant for Big Pharma companies like AstraZeneca, Fareva or Cephalon mainly for Lean Manufacturing implementation.
Teddy joined Sanofi Pasteur 10 years ago in Manufacturing Technology department first, then he moved to Global Engineering department as Technology Program Manager, where he is now leading the Primary Containers Identification Program.
Teddy has a strong and extensive expertise in pharmaceutical Filling & Packaging and is supporting different industrial projects related to Datamatrix coding, anti-counterfeiting measures and new packaging implementation.
Holger Krenz isresponsible for the European customer activities to support the commercialization of SiO2 ?sproduct portfolio. He is a biologist with a focus on Neurophysiology working for the last 16years in the medical device industry in various positions including R& D project management aswell as sales and business development at different companies e.g. Boehringer Ingelheim andWestRock / Silgan Dispensing. In 2014 he joined SiO2 Medical Products to support and managethe European customer activities.
Thierry co-founded Kurma in 2009. He has 25 years of experience in the Life Science Venture industry and is a Pharmacist and PhD by training. Thierry started his career in Japan as a scientific representative for Laboratoires Fournier (1992-1996). Having then studied at Insead, he joined Flamel Technologies as project director for Pharmaceutical R&D, after its IPO on the Nasdaq (1997-1998). He then moved to the investment world, first at Caisse des Dépots (1998-2005), then to AGF Private Equity (2005-2009), where he supervised the healthcare investment team. Thierry led investments in companies like Actelion, Arpida, Targacept, Adocia, Auris, Erytech or Safe Orthopaedics. He is currently on the Board of Directors of Meiogenix, Pathoquest, Blink Biomedical, Asarina Pharma and Minoryx.
With a mechanical and plastic background , Jean-Jacques Legat managed innovation and R&D teams in different sectors of activities : Aeronautics, Automotive and Health.
In Health , Jean-Jacques was the CEO of the ARaymond subsidiary dedicated in pharmaceutical and primary packaging products. Then he became technical and industrial director for the french plastics and composites competitiveness cluster Plastipolis to help the companies to collaborate and innovate.
Franck Lescure is Partner in charge of Life Sciences investments at Elaia Partners. Until 2018, Franck was Partner in charge of Life Sciences activities at Auriga Partners. Between 1990 and 1995, he has participated to the initial years of Genset, one of the first French biotech startups. Between 1997 and 2002, he joined the Air Liquide group in its healthcare subsidiary, followed by 2 years as member of the Venture Capital team of Crédit Lyonnais Private Equity. Franck Cumulates 28 years of experience in technology innovation, including 17 years in Capital Venture. He notably led investments in TxCell, Median or Erytech and he is currently on the board of directors of Amoeba, Enobraq, Fabentech, Flash Tx, Nosopharm, Pherecydes and Pylote.
Franck is an alumnus of the Ecole Normale Supérieure and of the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.
Lionel is R&D Associate Director at BD responsible for Design, Development and Life Cycle Management activities for Autoinjectors and Safety solutions. Lionel joined BD in 2005 and held roles of increasing responsibilities within R&D. He has a deep experience in Drug Delivery Systems Design and Development from Innovation stage to commercialization. He developed in particular BD Physioject™ Autoinjector and is listed in many patents.
Prior to BD, Lionel worked in the Automotive Industry. He has a Master’s Degree in Engineering with a specialization in plastic parts design and manufacturing.
William Matakas has worked within the pharmaceutical industry for over 15 years in areas of process engineering, operations and marketing. Currently in his role as Sr. Director, Product Management, Vial Containment & Delivery at West Pharmaceutical Services, William is responsible for defining new market requirements, launching new products, supporting business development plans, and overall execution of global marketing strategies for West.
Juha Mattila is Senior Product Manager for STERIS FINN-AQUA and STERIS VHP GMP Sterilization systems. He has bachelor’s degree in HVAC & Process Engineering and master’s degree in Business Informatics, both from Helsinki Metropolia University of Applied Sciences. He joined STERIS in 2000 and has nearly 19 years of experience with pharmaceutical and research process equipment and applications, including several years in R&D for STERIS FINN-AQUA products and systems. He has worked on several customer projects in Europe, North America and Asia, is an active conference presenter, and contributes to industry articles in professional journals. Juha is a member of PDA, ISPE and Finnish Biosafety Network and also a member of three ISO and CEN standard work groups.
Geert Moens has a Master degree in Public Administration and has been working at Datwyler for more than 11 years. After a successful career as Key Account Manager, working together with major pharmaceutical companies across Europe he is now the Global Platform Leader for Vial Closure Solutions taking strategic initiatives related to Datwyler’s rubber and aluminum closures for vial applications.
After finishing his studies in biology, Dr Novak completed his PhD in physics at the Max-Planck-Institute for Neurochemistry in Munich. He has held many leadership roles in research firms, biotech, and pharmaceutical equipment and packaging. In September 2018 he returned to Gerresheimer in a new global senior role for business development. Dr Novak’s focus has always been to improve the knowledge base of processes and discover new ways to optimize pharmaceutical processes based on scientific thinking which will serve the market needs.
Delphine Pernot est diplômée ingénieur agronome d’AgroParisTech et titulaire d’un Mastère en ingénierie et gestion de l’environnement à l’ISIGE Mines Paristech (2009). Elle débute sa carrière chez Airparif avant d’intégrer, en 2010, le cabinet Deloitte en tant que consultante puis manager Développement Durable.Sept années plus tard, Delphine Pernot rejoint l’équipe commerciale d’Adelphe. Sa missionest de construire une relation partenariale avec les clients et les parties prenantes issus principalement du secteur pharmaceutique notamment autour de l’éco-conception des emballages et accompagnement des entreprises dans leur stratégie RSE.
Anne-Catherine is dual qualified as both a pharmacist and a lawyer, specialising in pharmaceutical issues. She has in particular significant expertise on regulatory matters such as clinical trials, marketing authorisation, pricing and reimbursement, advertising. She also assists pharmaceutical companies in product liability cases, contractual or litigation arising from unfair competition. She also has experience in regulatory issues related to medical devices and food supplements. Anne-Catherine is a Senior Lecturer (professeur agrégé des universités) in pharmaceutical law at the University of Lille and directs a Masters degree in regulatory affairs.She is the author of La responsabilité du fait des médicaments. L'industrie pharmaceutique face à la loi du 19 mai 1998 (Medicinal Product Liability : the pharmaceutical industry and the law of 19 May 1998) and frequently publishes articles in national and international legal reviews on various subjects such as pharmaceutical liability, patients’ rights, clinical trials, pharmaceutical regulation, pricing, legal issues resulting from biotechnologies and the use of digital media. In December 2012 Anne-Catherine was awarded the French National Order of Pharmacists prize for her research into the liabilities of the pharmaceutical industry.
Dario Pirovano has been a consultant for regulatory affairs with Eucomed since 2002. He worked in the European Commission for 4 years, where he contributed to the drafting and negotiating of the 90/385 /EEC and 93/42/EEC directives.
Dario has over 30 years experience in medical technology as designer and regulatory affairs expert. In 1995 he founded Pirovano Management SPRL, a consulting firm advising manufacturers, Notified Bodies and authorities in regulatory matters relating to medical technology.
Mathieu Quintin joined VCLS in 2016 and works on projects involving the design and the execution of regulatory and clinical strategies for innovative medical devices. Mathieu assists Startups, SME and International Companies from early development phases to market registration – including global clinical development plans, submission strategies of clinical trial applications in Europe, interactions with regulatory bodies (Notified Bodies and national health Competent Authorities), assistance with Technical Files preparation and support of Post-market medical device activities.
Dr Joël Richard is currently Head of Technical &Pharmaceutical Operations at MedinCell (Montpellier, France). He is leading all the pharmaceutical development and non-clinical pharmaco/toxico-kinetic activities of the company, specialized in the development of Long-Acting Injectables. (LAIs), using theproprietary technology BEPO®. Dr Richard has 30 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as: -Senior Vice President, Pharmaceutical Development –Peptides in Ipsen (France),-Vice President, Drug Product Development in Ipsen (France),-Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany),-Vice President Research, and Europe R&D Director at Ethypharm (France),-COO atMainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems. Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug deliverysystems (such as microspheres, nanosystems, gelling systems, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. Dr Richard has graduated from Ecole Normale Supérieure (Cachan, France). He has got a PhD in Materials Science from University of Paris, France, and the “Habilitation à Diriger les Recherches” degree in Chemistry from University of Bordeaux I. He has published 68 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery systems, supercritical fluids, protein formulations, nanoparticles, etc.). He is the author of more than 140 international communications and 55 patent families.
Mathias Romacker is Senior Director, Device Strategy at Pfizer HQ in New York City. He joined Pfizer in March 2015. In this role within Pfizer Global Supply he focuses on the front end of device technology. He works with multiple functions and sites across the organization to develop a device strategy for Pfizer pipeline and inline products.
Previously Mathias worked over 9 years in the device area for Amgen in Thousand Oaks, California.
Before joining Amgen he held multiple sales and marketing positions with Becton Dickinson and Gerresheimer in Germany, South Africa and New Jersey.
Mathias holds a masters equivalent degree in economics from the University of Freiburg/Germany.
Alexander Roussanov is a counsel of our Life Sciences practice and advises clients on a broad range of issues relating to the EU and national regulatory framework governing the marketing of medicinal products and medical devices. Through his work in private practice, pharmaceutical companies and the European Medicines Agency (EMA), Alexander acquired extensive first-hand experience in dealing with highly sensitive and complex regulatory matters, access to documents and clinical data disclosure. Building upon this experience, he delivers practical, clear and effective advice to clients in relation to regulatory strategies and interactions with the regulators.
Guilhem Rousselet has been in charge of Global Packaging for Sanofi Group for the last 5 years, and is leading the serialization project for Sanofi.
Page 7of 11Before joining Sanofi, he had several experiences in Packaging Development in mass market companies in home care and cosmetics.
As counsel of our Life Sciences practice, Fabien Roy focuses his practice at Hogan Lovells on advising clients on European Union (EU) and national regulatory matters involving medical devices and pharmaceutical laws and guidelines. Fabien follows the new regulations on medical devices (MDR and IVDR) and the GDPR very closely and regularly advises clients on the requirements applicable to their digital health technologies. With a practice entirely focusing on complex regulatory issues faced by Life Sciences clients, he can quickly address and anticipate complex challenges and propose innovative solutions enabling clients to focus on their business.
Volker Rupertus is active as Senior Principal Expert at the Business Unit Pharmaceutical Systems of the SCHOTT AG, Mainz, Germany.
He began his industrial career in 1995 joining the R&D department of SCHOTT. From 2000 to 2010 he headed the R&D-division “Process Development & Characterization” serving all Business Units of SCHOTT.
In 2010, he joined the Pharmaceutical Systems business unit as head of global quality. Rupertus, who graduated from the University of Kaiserslautern with a degree in technical physics and a PhD in glass surface science, frequently gives lectures in materials analysis and was made a honorary professor by the Technical University of Clausthal.
Christian Schierholz is Corporate Development Manager and Venture Associate at Sanner Ventures GmbH. Within the Sanner Group, Sanner Ventures aims to explore new business areas and is devoted to products and solutions that help protect patient health and facilitate patient engagement.
Christian has 10 years of business development and strategy experience and worked in the telecommunication, pharmaceutical and healthcare sector in Germany, South East Asia and the US.
Hans-Martin Schwarm, Ph.D., is Licenced Pharmacist, Certified Food Chemist, Pharmacist for Pharmaceutical Analysis, and Pharmacist for Pharmaceutical Technology. He has over 30 years of experience in pharmaceutical industry at various positions on senior and corporate management level for Quality Assurance and Quality Management, Technical Operations and Supply Chain, Regulatory, Product Development and Technology Transfer. He was with American Home (now Pfizer), STADA, and AET. He also served as Qualified Person and QP Pharmacovigilance, and was responsible for international project in Europe, US, India, and China. Today he acts as Senior Advisor Pharma and Health Care providing advanced solutions for the pharma and health care industry.
Sai Shankar is Director for Connected Devices Business Development at Aptar Pharma. Sai has 15 years of
product development and business strategy experience in the pharmaceutical industry. He joined Aptar
in April 2017, with previous stints at Allergan and Sanofi.
With 30 years of experience in the field of Medical Devices, In-Vitro Diagnostic and
Pharmaceutical Packaging, Pascal Sircoulomb has been holding sales, marketing and
management positions within large international companies (BD, Danaher/Leica) as well as
start-up biotechs. He has joined ARaymondlife in 2018 as Business Development Director.
Ger Standhardt is Executive Director of the Healthcare Compliance Packaging Council of Europe (HCPC Europe). HCPC Europe is a not for profit organisation. The mission of HCPC Europe is to educate the healthcare sector in the improvement of patients’ compliance by promoting packaging that improves patients’ lives. One of HCPC Europe’s key objectives is to achieve demonstrable improvements in patients’ lives, as well as enhanced compliance and adherence to medication regimens by facilitating knowledge sharing in the area of patient-friendly pharmaceutical packaging.
Ger studied Industrial Design Engineering at Delft University of Technology and graduated on the Airline Meal of the Future (March 2007), an application case for RFID in airline catering. Since his graduation he has been working at the NVC Netherlands Packaging Centre as manager Knowledge Development & Projects. He is responsible for the content of the training and educational activities, like the NVC Course Programmes in Packaging for middle and upper management, and for setting up and running new projects. He has been running the NVC Project Pharmaceutical Packaging Innovation since 2011. In this project NVC-members share innovative solutions with each other in order to come to improvements or new applications together. The main themes are accessible design, authenticity, and improving patient adherence.
On 1 July 2015 he took on the role of Executive Director of HCPC Europe. Running HCPC Europe is part of his current job at the NVC Netherlands Packaging Centre.
Yves Steffen has over 15 years of experience in the pharmaceutical industry. In 2004 he began his career for Cilag AG (a Johnson & Johnsoncompany) as project engineer for drug product manufacturing and visual inspection lines. In 2006 he joined Novartis and held there several positions in commercial manufacturing covering engineering, product launches / transfer and commercial product responsibilities for Biosimilars. Since 2014 his focus area was medical devices and combination products and since 3 years Yves Steffen is heading the commercialization group of medical devices and combination products including secondary packaging for Novartis.
Packaging Engineer graduated from former-ESIEC (now ESIREIMS), Packing and Packaging Engineer School from Reims, Arnaud Steiner evolves in this world of packaging since his beginnings. After 5 years in pharmaceutical industry for human health at AstraZeneca, on sites of Reims and Dunkerque, he continued for 10 years in the food industry at Hochland near Verdun.Since 3 years, he is now in pharmaceutical industry for animal health at Virbac, the 7th veterinary company worldwide, where he is head of primary packaging development in the Corporate pharma R&D department.
Dr. Oliver Sude is the Deputy Secretary General and General Counsel of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org), the voice of small to medium-sized pharmaceutical companies, in particular those that are active in the field of rare diseases.
Oliver is a German qualified lawyer with 18 years’ experience in the field of life sciences. Before joining EUCOPE, he worked with international law firms focusing on EU regulatory affairs, intellectual property and market access issues. He heads EUCOPE’s Brexit Task Force.
Dan-Ola Svenssonhas over 30 years of experience in the world of thermoplastics. Hespent the early years as quality engineer with a major injection molding company,serving the automotive industry and laid the foundation to his profound interest forquality management systems, Leadership for quality and quality improvements.While keeping his initial interest area, he moved further into the world ofcompounding of standard and engineering plastics, driving developments within thequality-and laboratory management systems.Furthermore, innovation became a key area leading to special raw material-andcompound solutions.He joined Clariant in 1997. After a position within quality-and laboratorymanagement, in 1999 Dan-Ola became technical manager for the Malmoe/Swedishmasterbatch manufacturing site, focusing on technical-and regulatory innovations ofprocesses, products and services. In 2010, in relation to Clariant implementing a dedicated medical-and healthcareorganization and the brand name of Mevopur, he became regional technical managerfor Europe within segment Healthcare Polymer Solutions.
Charbel Tengroth is an experienced professional having worked in various leader roles within the fields of aseptic drug product and process development, and medical devices and combination products. Charbel has a strong scientific background holding a PhD in physics from Chalmers Institute of Technology and a post-graduate research positions at Princeton University and AstraZeneca R&D, which has given him the ability to very quickly get to the core of complex issues. He is currently working as an independent consultant for the pharma industry within his field of expertise. Before starting his own company, Charbel was Technical Director at SHL Medical, a world-leading developer and manufacturer of medical devices. As Head of Device Development, Charbel managed multi-disciplinary teams of design engineers, human factor engineers, and industrial designers.Charbel came to SHL Medical from Pfizer where he managed a team of scientists working with process development and drug product characterization of aseptic and biological drug products, and medical devices (injectors, inhalers, and others). He also led several product technology transfers and was managing an aseptic formulation and filling pilot plant.Over the years Charbel has contributed to the success of a wide range of pharmaceutical products and medical devices such as Prevnar 13, Genotropin, Depo-Provera/Sayana, and the DAI and Molly families of injection devices.
Yves Th. Tillet is a doctor in pharmacy, graduate of physiology and biochemistry, of the Business Administration Institute, and of Marketing and Strategy from the Centre for Higher Education. Yves Th. Tillet began his professional career in the field of hospital biology and clinical pharmacy. In 1994, Yves Th. Tillet created with and Marie D. White the Cabinet WHITE-TILLET providing expertise in quality, assessment, and regulation of health products. Yves Th. Tillet has taught at several French universities and is author of numerous publications.
As an Account Executive for GlobalVision, a global technology company with ISO certification that develops software and hardware solutions to highly regulated industries including Pharmaceutical and Medical Device. William works with companies worldwide to help them streamline their quality control process, including new product rollouts, customer relationship development and order fulfillment.
Charlotte started her career as a Belgian business lawyer (corporate and commercial law). Triggered by the clients' businesses, she gained experience in international strategic sales & marketing within highly regulated environment e.g. pharma (Pfizer), medical devices (Medline, 3M) and sterilization (STERIS AST). Currently being commercial manager within STERIS AST, she is involved in business
development, managing teams, strategic decision making, contract negotiations and networking.
Dr. Kerstin Walke is the Head of Pharmaceutical Development Biologicals at Boehringer Ingelheim with a doctor of philosophy in Chemistry. She has more than 17 years of experience in the biopharmaceutical field and in Technology & Innovation. She was Manager of Corporate Development Biooharma after her traineeship. In 2011 she builded up Technology & Innovation within the Biopharmaceutical Department. In 2015 she became Head of Pharmaceutical Development Biologicals being accountable for formulation, primary packaging and combination product development.
Susanna White has worked as a Device Development Engineer at Oval Medical Technologies for thepast 6 years, where she is involved in the design and test programmes for their innovative polymericPDC. Much of her work has focused on the study of highly viscous and non-Newtonian drugformulations -using numerical modelling techniques in combination with experimental investigationin order to achieve the most appropriate delivery system for challenging formulations. Susannagraduated from the University of Cambridge with a Master’s Degree in Engineering for the LifeSciences.
Dr Gerallt Williams is Director Scientific Affairs at Aptar Pharma. After obtaining his PhD from the
University of Wales, UK in 1985, Gerallt has held various industrial positions at Monsanto Inc. (UK),
Fisons Ltd (UK), Valois (France) and Inhale/Nektar Therapeutics (USA).
Gerallt is now in charge of Scientific Affairs for the Aptar Pharma Prescription division, Le Vaudreuil,
France and is engaged in the development of new devices for nasal, inhaled and injectable drug
Jingwei ZHANG is currently R&D director of SGD Pharma, based in France.
Previously to this position, he worked for Saint-Gobain Group for more than 20 years, as strategic project manager and R&D portfolio manager. He has a large experience in glass products and glass process.
He is inventor of more than 70 international patents.
He is member of TC12 (Technical Committee 12 for pharma glass packaging) under ICG (International Commission on Glass).
Jingwei ZHANG graduated from Harbin Institute of Technology in China and received his Ph.D in France.